Martinsried, Germany — Affectis Pharmaceuticals AG today announced that Dr. Stephen
Murray has been appointed as Chief Medical Officer (CMO).
“Steve brings significant relevant drug development expertise which will be valuable to us
as cimicoxib advances through Phase II clinical trials,” remarked Alex Martin, Chief
Executive Officer for Affectis. “We believe Steve is ideally suited to lead our efforts with the
FDA this fall and we are delighted to bring him on board. His appointment marks a major
milestone for the company as we shift our focus to our later stage programs.”
“I am happy to be joining Affectis at this exciting time and I look forward to working with
the team to advance meaningful treatments for central nervous system diseases where
there are still significant unmet medical needs,” stated Dr. Murray.
Dr. Murray has held a number of positions in the pharmaceutical industry including Chief
Medical Officer at Memory Pharmaceuticals before it was sold to Roche in 2009. Prior to
Memory he was with Pfizer Pharmaceuticals, most recently as Senior Medical Director,
Worldwide Medical Team Leader, Schizophrenia, and Chair, Schizophrenia, Bipolar and
Cognition Disease Area Leadership Team. Prior to joining Pfizer, Dr. Murray was an
Associate Medical Director at Janssen Pharmaceuticals. Dr. Murray completed his clinical
training in the Department of Psychiatry at the University of California, San Francisco and
was a research fellow at UCSF where his work focused on the cellular trafficking of G-protein
coupled receptors. Dr. Murray received a B.S. from the University of South Carolina in
Columbia, and both his M.D. and Ph.D. from the Medical University of South Carolina in
Charleston.The Acoma Group LLC, www.acomagroup.com 203-423-9494, an executive search firm with expertise in pharmaceutical, biotech and medical device located in Connecticut conducted the search.
About Affectis Pharmaceuticals AG
Affectis Pharmaceuticals is a biopharmaceutical company focused on novel concepts for the
treatment of psychiatric disorders and inflammatory diseases. The company discovers and
develops drugs based on pioneering findings in the fields of depression, schizophrenia, and
inflammation. Affectis was a spin-out from the Max-Planck Institute of Psychiatry in 2004,
and since then has successfully advanced several compounds into the company’s
development pipeline. The company’s lead compound, cimicoxib, is currently completing a
European Phase IIa study in depression. For further information, please visit:
www.affectis.com
